15-12G - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

POSASR - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

POS AM - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

POS AM - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

POS AM - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

POS AM - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

SC 13G - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

HC Wainwright & Co. downgraded Arena Pharmaceuticals from Buy to Neutral and set a new price target of $100.00 from $120.00 previously

Cantor Fitzgerald downgraded Arena Pharmaceuticals from Overweight to Neutral and set a new price target of $100.00 from $93.00 previously

JMP Securities downgraded Arena Pharmaceuticals from Market Outperform to Market Perform

SVB Leerink downgraded Arena Pharmaceuticals from Outperform to Market Perform and set a new price target of $100.00 from $112.00 previously

RBC Capital downgraded Arena Pharmaceuticals from Outperform to Sector Perform and set a new price target of $100.00 from $76.00 previously

Credit Suisse downgraded Arena Pharmaceuticals from Outperform to Neutral and set a new price target of $100.00 from $98.00 previously

Jefferies downgraded Arena Pharmaceuticals from Buy to Hold and set a new price target of $100.00

Needham downgraded Arena Pharmaceuticals from Buy to Hold

Wells Fargo initiated coverage of Arena Pharm with a rating of Overweight and set a new price target of $71.00

Cantor Fitzgerald reiterated coverage of Arena Pharmaceuticals with a rating of Overweight and set a new price target of $93.00 from $100.00 previously

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development, reporting to Amit D. Munshi, President and CEO of Arena. Dr. Manion brings more than 20 years of pharmaceutical industry experience spanning three large companies, including work in all of Arena's therapeutic areas. "We are excited to have Dr. Manion join the Arena team," said Mr. Munshi. "Doug has leadership experience across all aspects of research and development, as well as extensive international experience, which will guide Arena R&D as we continue to grow and progress our portfolio." "I was attracted by the breadt

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Steven Schoch to the Company's Board of Directors and as Chair of the Audit Committee. Mr. Schoch brings more than 20 years of financial and operational leadership and expertise across a range of areas in biopharmaceuticals, media, and technology, including building and scaling businesses and leading innovation. "We are very pleased to have Mr. Schoch join our Board of Directors," said Garry Neil, M.D., Chair of the Board of Directors of Arena. "Steven brings both financial and strategic operational experience that will be of great benefit as Arena prepares for the next stage of growth." Mr. Schoch currently serv

SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to the Company’s Board of Directors. Garry Neil, MD, has been appointed Chair of the Board. Additionally, Nawal Ouzren has been appointed as a new Board member. “These changes in our Board leadership will help position Arena for the growth we anticipate and mark an important inflection point in our progress,” said Amit D. Munshi, President and CEO of Arena. “Garry Neil has served on the Board for the past four years, providing exceptional leadership for our scientific direction. As a physician with extensive industry experience, his insight into successfully translating scientific disco

– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets. About Arena Pharmaceuticals ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done. ARENA - Care More. Act Differently. Forward-Looking Statements Certain statements in this press relea

Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases Expands innovative pipeline potentially enhancing growth through 2025 and beyond Transaction valued at $100 per Arena share in cash, for a total equity value of approximately $6.7 billion Pfizer to host analyst and investor call at 10am EST today with Pfizer I&I executives Pfizer Inc. (NYSE:PFE) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapie

–  Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout –  First participant randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis –  Strong liquidity position to support continued pipeline progress Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021. "During the quarter, the team continued to make significant progress across all key programs, including reaching full enrollment for the ELEVATE UC 12 program," said Amit D. Munshi, President and CEO of Arena. "ELEVATE UC 12 and ELEVATE UC 52 remain on track and we continu

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its third quarter 2021 financial results and provide a corporate update on Thursday, November 4, 2021, after the close of the U.S. financial markets. The Company will host a question and answer session via conference call and live webcast with the investment community the same day at 4:30 PM ET. Conference Call & Webcast Information When: Thursday, November 4, 2021, at 4:30 PM ET Webcast: Conference call will be broadcast live in listen-only mode on the company's investor relations website at https://invest.arenapharm.com/events-presentations A recording of the conference call will be archived for 30 days after the call. About Arena

– Phase 3 ELEVATE UC 12 trial reached full enrollment; topline data expected Q1 2022 with ELEVATE UC 52 – Liquidity position at ~$1.0 billion as of June 30, 2021 to support continued pipeline progress Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021. "With today's announcement of the ELEVATE UC 12 trial reaching full enrollment, we look forward to a potentially transformational data readout of ELEVATE UC 12 and ELEVATE UC 52 in the first quarter of next year. We are also pleased with our recently announced partnership with Aristea to strengthen our mid-stage immunology pipeline," said Ami

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its second quarter 2021 financial results and provide a corporate update on Thursday, August 5, 2021, after the close of the U.S. financial markets. The Company will host a live webcast to discuss the results with the investment community the same day at 4:30 PM ET. Conference Call & Webcast Information When: Thursday, August 5, 2021, at 4:30 PM ET Webcast: Conference call will be broadcast live in listen-only mode on the company's investor relations website at https://invest.arenapharm.com/events-presentations. A recording of the conference call will be archived for 30 days after the call. About Arena Pharmaceuticals ARENA Pharmac

Agreement Provides Arena with Exclusive Option to Acquire Aristea and its CXCR2 Programs post-Phase 2 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Aristea Therapeutics, Inc. today announced a strategic collaboration to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed by Aristea for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases. Under the terms of the agreement, Arena will provide a $60 million upfront payment to Aristea and a $10 million equity investment in Aristea's Series B financing. In return, Aristea has granted Arena an exclusive option to acquire Aristea, including rights to all CXCR2 programs, upon com

– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of February 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement RSUs vest over four years, with 25% of the shares vesting on the first designated quarterly vesting date on or following the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in 12 substantially equal quarte

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets. About Arena Pharmaceuticals ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done. ARENA - Care More. Act Differently. Forward-Looking Statements Certain statements in this press relea

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement restricted stock units ("RSUs") to new employees. The inducement RSUs have a grant date and vesting commencement date of January 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). These grants included: RSUs to Malcolm Crooks, Senior Vice President, Head of International, at an amount of 15,111 shares, approved by the Compensation Committee on January 11, 2022; and 20,218 RSUs to 21 new employees, approved by the Compensation Committee on January 11, 202

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 16 new employees 28,659 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of December 15, 2021 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement RSUs vest over four years, with 25% of the shares vesting on the first designated quarterly vesting date on or following the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in 12 substantially equal quarte

Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases Expands innovative pipeline potentially enhancing growth through 2025 and beyond Transaction valued at $100 per Arena share in cash, for a total equity value of approximately $6.7 billion Pfizer to host analyst and investor call at 10am EST today with Pfizer I&I executives Pfizer Inc. (NYSE:PFE) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapie

- Evaluating 2 mg and 3 mg etrasimod in study participants with moderate to severe Crohn's Disease (CD) - Topline data from CULTIVATE Study A on track for Q2 2022 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that it has achieved target enrollment in Study A of the Phase 2/3 CULTIVATE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate to severe Crohn's disease (CD). CULTIVATE Study A reached target enrollment of 70 study participants to assess etrasimod 2 mg and 3 mg in participants with CD. "Crohn's disease patients have an intense need for additional ther

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 23 new employees inducement stock options to purchase an aggregate of 39,400 shares of its common stock and 18,760 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of November 15, 2021 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options are non-qualified stock options, have a seven-year term, have an exercise price of $58.85 per share, the closing price of Arena's co

–  Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout –  First participant randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis –  Strong liquidity position to support continued pipeline progress Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021. "During the quarter, the team continued to make significant progress across all key programs, including reaching full enrollment for the ELEVATE UC 12 program," said Amit D. Munshi, President and CEO of Arena. "ELEVATE UC 12 and ELEVATE UC 52 remain on track and we continu

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options and inducement restricted stock units ("RSUs") to new employees. The inducement stock options and RSUs were approved by the Compensation Committee on October 5, 2021 and each have a grant date and vesting commencement date (if applicable) of October 15, 2021, and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). These grants included: options to purchase an aggregate of 36,000 shares of Arena's common stock to Lamine Mbow, Senior Vice President and Chief

GAINERS: Nine Energy Service (NYSE:NINE) shares closed up 57.66% at $5.66 ReneSola (NYSE:SOL) shares closed up 36.36% at $8.10 GrowGeneration (NASDAQ:GRWG) shares closed up 11.07% at $8.53 Cara Therapeutics (NASDAQ:CARA) shares closed up 11.00% at $11.71 MedMen Enterprises (OTC:MMNFF) shares closed up 10.36% at $0.12 Item 9 Labs (OTC:INLB) shares closed up 8.42% at $1.03 Corbus Pharmaceuticals (NASDAQ:CRBP) shares closed up 7.06% at $0.34 Cansortium (OTC:CNTMF) shares closed up 6.36% at $0.50 Arena Pharmaceuticals (NASDAQ:ARNA) shares closed up 5.36% at $98.64 Village Farms Intl (NASDAQ:VFF) shares closed up 5.25% at $4.41 Charlottes Web Holdings (OTC:CWBHF) shares closed up 4.57% at $1.03

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) revealed Wednesday financial results for the fourth quarter and full year ended Dec. 31, 2021. Q4 Finanical HIghlights Net loss for the fourth quarter was $155.6 million compared to a net loss of $122.2 million for the same period in 2020 Basic and diluted net loss per share for the fourth quarter was $2.54 compared to basic and diluted net loss per share of $2.10 for the same period in 2020 Research and development (R&D) expenses for the fourth quarter totaled $110.3 million compared to $100.4 million in the same period in 2020. This increase was primarily driven by our advancing clinical studies, including the etrasimod Phase 3 program, as w

Arena Pharmaceuticals (NASDAQ:ARNA) reported quarterly losses of $(2.54) per share which missed the analyst consensus estimate of $(2.26) by 12.39 percent. This is a 20.95 percent decrease over losses of $(2.10) per share from the same period last year. The company reported quarterly sales of $54.00 thousand which missed the analyst consensus estimate of $660.00 thousand by 91.82 percent. This is a 45.95 percent increase over sales of $37.00 thousand the same period last year.

Arena Pharmaceuticals (NASDAQ:ARNA) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Arena Pharmaceuticals missed estimated earnings by 12.39%, reporting an EPS of $-2.54 versus an estimate of $-2.26. Revenue was up $17.00 thousand from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.68 which was followed by a 3.32% drop in the share price the next day. Here's a look at Arena Pharmaceuticals's past performance:   Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020 EPS Estimate -2.53 -2.19 -2.16 -1.85

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences Inc. (NASDAQ:KOD) announced negative top-line results from its Phase 2b/3 clinical trial evaluating the KSI-301 in treatment-naïve subjects with neovascular age-related macular degeneration. The study did not meet the primary efficacy endpoint of showing non-inferior visual acuity gains for subjects dosed on extended regimens compared to aflibercept given every eight weeks. The stock was sinking 70.86% to $14.67 in premarket trading. Akebia's Announces Expanded Agreement With Vifor Regardin

  Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM) is projected to report earnings for its fourth quarter. • Physicians Realty Trust (NYSE:DOC) is estimated to report earnings for its fourth quarter. • Eneti (NYSE:NETI) is expected to report quarterly loss at $0.21 per share on revenue of $28.21 million. • Avanos Medical (NYSE:AVNS) is projected to report quarterly earnings at $0.40 per share on revenue of $191.32 million. • Fresh Del Monte Produce (NYSE:FDP) is likely to report earnings for its fourth quarter. • Gerdau (NYSE:GGB) is likely to report quarterly earnings at

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug Administration approved Agios Pharmaceuticals, Inc.'s (NASDAQ:AGIO) mitapivat for treating pyruvate kinase deficiency, a rare, inherited metabolic disorder. Avenue Therapeutics, Inc. (NASDAQ:ATXI) stock tumbled close to 60% after an FDA panel found that data included in the company's new drug application for pain drug tramadol was inadequate to support approval. GlaxoSmithKline plc (NYSE:GSK) and Sanofi (NASDAQ:SNY)-Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) suffered setbacks after their r

Arena Pharmaceuticals (NASDAQ:ARNA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 7 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 6 0 0 3M Ago 0 1 0 0 0 In the last 3 months, 8 analysts have offered 12-month price targets for Arena Pharmaceuticals. The company has an average price target of $96.38 with a high of $100.00 and a low of $71.00. Below is a summary of how these 8 analysts rated Arena Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings,

  Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment earned $1.51 in the third quarter, compared to $1.12 in the year-ago quarter. At the moment, the stock has a 52-week-high of $140.51 and a 52-week-low of $90.16. Federal Realty Investment closed at $122.79 at the end of the last trading period. Check out this: Executives Buy Around $64M Of 3 Stocks According to SVB Leerink, the prior rating for Tenet Healthcare Corp (NYSE:THC) was changed from Market Perform to Outperform. In the fourth quarter, Tenet Healthcare showed an EPS of $2.70, compared to $4.72 from the yea

HC Wainwright & Co. analyst Patrick Trucchio downgrades Arena Pharmaceuticals (NASDAQ:ARNA) from Buy to Neutral and lowers the price target from $120 to $100.